← FDA DRUG APPROVALS

FDA ANDA · ANDA209063

RIVASTIGMINE TRANSDERMAL SYSTEM

rivastigmine

Sponsor: BRECKENRIDGE

APPLICATION
ANDA209063
TYPE
ANDA
ORIGINAL APPROVAL
2019-11-26
LATEST ACTION
2019-11-26
ROUTE
TRANSDERMAL
DOSAGE FORM
FILM, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

RIVASTIGMINEPrescription
RIVASTIGMINE 13.3MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
RIVASTIGMINEPrescription
RIVASTIGMINE 4.6MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
RIVASTIGMINEPrescription
RIVASTIGMINE 9.5MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL

Approval history

2019-11-26UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →